The Drug, Trial and Commercial
Landscape
A review of the DDR drug landscape, analysing by target and repair pathway, the trial landscape, comparing the diseases, biomarkers and combination therapies that are being evaluated and the DDR deals & companies landscape.
The Endometrial Cancer Landscape and Future of DDR
A look into how PARP inhibitors are being investigated in the treatment of endometrial cancer, focussing specifically on their combinations with immune checkpoint modulators and insight into the emerging combination between DDR inhibitors (DDRi’s) and antibody-drug conjugates (ADC’s).
About the report
The two part-analysis includes:
-
- The Drug and Trial Landscape – An analysis of the 650+ DDR-related drugs and 1,650+ trials hosted on Beacon DDR
- Commercial Landscapes – An overview of the commercial landscape, looking into deals and companies analysed by target, deal type and geographical location
- The Endometrial Cancer Landscape – Insight into the endometrial cancer landscape off the back of the first DDR approval for endometrial cancer treatment
- The Future of DDR – A look into emerging combination therapies along with the drugs to keep an eye on in 2024
You may also be interested in...
The 2024 DDR H1 Landscape Review
Investment Trends in Early-Stage Biopharma: A Beacon Data Perspective
Beacon DDR: ASCO Post-Conference Report 2024
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
Speak with our team
Our dedicated account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.
